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Background
BAY 63–2521 is an oral soluble guanylate cyclase (sGC)
stimulator that acts independently of nitric oxide (NO). It
targets the reduced form of sGC, and enhances the sensi-
tivity of the enzyme to low levels of bioavailable NO. Pre-
clinical data suggest that BAY 63–2521 has the potential
to be effective in the treatment of pulmonary hyperten-
sion, with the advantage of having a different mode of
action from currently available agents.
Materials and methods
This randomized, placebo-controlled, single-blinded
study assessed the safety, tolerability, pharmacodynamics
and pharmacokinetics of orally administered BAY 63–
2521 in healthy male volunteers. Subjects received a sin-
gle oral dose of BAY 63–2521 in solution (0.25 mg, n = 6;
0.5 mg n = 5; 1 mg, n = 12; 2.5 mg, n = 6; 5 mg, n = 10) or
as an immediate-release tablet (2.5 mg, n = 6), or match-
ing placebo solution (n = 11) or a placebo tablet (n = 2).
Safety parameters (adverse events [AEs], electrocardio-
grams [ECGs] and standard laboratory values), pharma-
codynamics (heart rate [HR], systolic blood pressure
[SBP], diastolic blood pressure [DBP], cyclic guanosine
monophosphate [cGMP] levels and plasma vasoactive
hormone levels) and pharmacokinetics were assessed.
Results
Overall, 72 AEs (66 mild, 6 moderate) were reported in 29
of 58 subjects. Forty-eight AEs occurring in 20 (44%) of
45 individuals receiving BAY 63–2521 were attributed to
the study compound. The rate of AEs was dose-depend-
ent. No serious AEs occurred, and all except one (stretched
ligament, left ankle joint – lost to follow up) were found
to have resolved by study completion. BAY 63–2521 had
no clinically relevant effects on ECGs or laboratory values.
Pharmacodynamic evaluation showed that BAY 63–2521
increased HR in a dose-dependent manner (P < 0.0001;
Table 1). In healthy young subjects, the cardiovascular
system compensates for changes in blood pressure with
changes in HR to keep the blood pressure constant as long
as possible. Therefore, HR is considered the most sensitive
non-invasive parameter for indirect estimation of the
effect of a vasodilating agent on the cardiovascular system.
Pharmacodynamic evaluation also showed that BAY 63–
2521 reduced mean DBP in the 2.5 mg and 5.0 mg dose
groups; SBP was not significantly affected. In terms of
vasoactive hormones, BAY 63–2521 dose-dependently
increased plasma renin activity (P < 0.0001) and
noradrenalin levels (P = 0.0099), while having no signifi-
cant effects on aldosterone or angiotensin II levels. Plasma
levels of cGMP increased dose-dependently (P < 0.0001).
The two 2.5 mg formulations of BAY 63–2521 (oral solu-
tion and immediate-release tablet) exhibited similar bio-
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availability. BAY 63–2521 pharmacokinetics showed high
inter-individual variability.
Conclusion
BAY 63–2521 had a favourable safety profile and was
well-tolerated up to a single oral dose of 5 mg. In line with
its mode of action as an sGC stimulator, BAY 63–2521
dose-dependently reduced DBP and increased HR. Further
studies are warranted to assess the therapeutic potential of
BAY 63–2521 in patients with pulmonary hypertension.
Table 1: Increase in heart rate after oral administration of BAY 63–2521 in solution, compared with placebo.
Dose Increase in heart rate (beats/minute) 95% confidence interval P value
0.25 mg -1.35 (-5.10 to 2.40) 0.4726
0.5 mg 0.44 (-3.45 to 4.32) 0.8218
1.0 mg 4.09* (1.10 to 7.08) 0.0084
2.5 mg 7.77* (4.22 to 11.32) <0.0001
5.0 mg 11.34* (8.29 to 14.39) <0.0001
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